Showing 4061-4070 of 10742 results for "".
- Rubedo Plans Clinical Trial of RLS-1496 for Androgenetic Alopeciahttps://practicaldermatology.com/news/rubedo-plans-clinical-trial-of-rls-1496-for-androgenetic-alopecia/2488446/Rubedo Life Sciences announced plans to evaluate its investigational GPX4 modulator RLS-1496 in patients with androgenetic alopecia (AGA), following ex vivo findings showing increased growth of human hair follicles exposed to the agent, according to an a
- Meta-Analysis: IBD Events Are Rare With IL-17 Inhibitors in HShttps://practicaldermatology.com/news/meta-analysis-finds-rare-ibd-events-with-il-17-inhibitors-in-hs/2488443/Interleukin (IL)-17 inhibitors were not associated with a statistically significant increase in inflammatory bowel disease (IBD) risk among patients with hidradenitis suppurativa (HS) in a systematic review and meta-analysis published online in JAMA Dermatology. IBD Events Remain
- FDA Grants Priority Review to Zasocitinib for Plaque Psoriasishttps://practicaldermatology.com/news/fda-grants-priority-review-to-zasocitinib-for-plaque-psoriasis/2488421/The US Food and Drug Administration (FDA) has accepted Takeda’s new drug application (NDA) for zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis and granted the application Priority Review, according to a company announcement.
- Review Integrates Functional and Aesthetic BTX-A Treatment for Facial Paralysishttps://practicaldermatology.com/news/review-integrates-functional-and-aesthetic-btx-a-treatment-for-facial-paralysis/2488325/Botulinum toxin A (BTX-A) may offer dermatologists a way to address the functional, therapeutic, and aesthetic manifestations of facial paralysis within a single treatment framework, a recent review suggested.d BTX-A Targets Multiple Sequelae of Facial Paralysis The authors conduc
- Outpatient Dermatology Care Linked to Fewer HS Hospital Readmissions: Analysishttps://practicaldermatology.com/news/outpatient-dermatology-care-linked-to-fewer-hs-hospital-readmissions-analysis/2488266/Hidradenitis suppurativa (HS) carries a significant acute-care burden, but outpatient dermatology follow-up may be associated with fewer hospital readmissions, according to a study published in Archives of Dermatological Research
- Brepocitinib Improves Cutaneous Dermatomyositis Outcomes Through 52 Weekshttps://practicaldermatology.com/news/brepocitinib-30-mg-improves-cutaneous-dermatomyositis-outcomes-through-52-weeks/2488228/Once-daily oral brepocitinib 30 mg improved skin disease activity, pruritus, and skin-related quality of life in adults with dermatomyositis as early as 4 weeks, according to results from an analysis of phase data from the 3 VALOR trial. The analysis included data from 241 adults with acti
- Review Explores Energy-based Devices in Gender-affirming Carehttps://practicaldermatology.com/news/review-explores-energy-based-devices-in-gender-affirming-care/2488181/Laser and energy-based devices (EBDs) may address several dermatologic concerns relevant to transgender patients, from unwanted hair and acne to postoperative scars and body contouring, according to a recent review by Zarghami et al. Laser Applications Span Hair Removal, Acne, and Postsur
- Analysis: IBS Associated With 35% Higher Long-Term Risk of Psoriasishttps://practicaldermatology.com/news/analysis-ibs-associated-with-35-higher-long-term-risk-of-psoriasis/2488177/A large prospective cohort study showed a link between irritable bowel syndrome (IBS) and an elevated long-term risk of developing psoriasis compared to those without IBS.
- INTerpath-001: Intismeran Plus Pembrolizumab Meets Dual Phase 3 Melanoma Endpointshttps://practicaldermatology.com/news/intismeran-plus-pembrolizumab-meets-dual-phase-3-melanoma-endpoints/2488176/Merck and Moderna reported positive topline results from the phase 3 INTerpath-001 trial evaluating intismeran autogene (V940; mRNA-4157) plus pembrolizumab (Keytruda) as adjuvant therapy for completely resected stage IIB-IV cutaneous melanoma. The individualized mRNA-based neoantigen ther
- LEO Pharma Acquires Worldwide Rights to Dersimelagon for EPP, XLPhttps://practicaldermatology.com/news/leo-pharma-acquires-worldwide-rights-to-dersimelagon-for-epp-xlp/2488131/LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma, adding a late-stage investigational therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) to its rare dermatology pipeline. Under the agreement, LEO Pharma w